LEXICON
No.34 December 20, 2010

Investigator-initiated (clinical) trial:IIT
医師主導型臨床試験(治験)
Clinical trial; Clinical study; Clinical research
臨床治験; 臨床試験; 臨床研究
Investigator; Subinvestigators; Coordinating investigator
治験責任医師; 治験分担医師; 治験調整医師

Clinical trials (臨床治験 or 治験: abbreviation of 治療試験) are defined as studies conducted in humans, patients or healthy volunteers (健常志願者), with investigational new drugs (治験薬) or existing drugs (既存薬) for dual purposes: 1) to generate the data necessary to obtain...

To read the full story

LEXICON

By Hayate Horiguchi

The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…

By Philip Carrigan

The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

By Ken Yoshino

Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…

For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…

A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…